ENLV
ENLV
NASDAQ · Biotechnology

Enlivex Therapeutics Ltd

$1.05
-0.04 (-3.67%)
As of Mar 29, 10:31 PM ET ·
Financial Highlights (FY 2025)
Revenue
40.60M
Net Income
-1,409,045
Gross Margin
28.7%
Profit Margin
-3.5%
Rev Growth
+15.5%
D/E Ratio
0.48
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 28.7% 28.7% 28.7%
Operating Margin -4.5% -4.8% -4.2%
Profit Margin -3.5% -3.7% -4.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 40.60M 42.46M 39.37M
Gross Profit 11.67M 12.20M 11.31M
Operating Income -1,823,904 -2,022,071 -1,646,179
Net Income -1,409,045 -1,565,662 -1,719,749
Gross Margin 28.7% 28.7% 28.7%
Operating Margin -4.5% -4.8% -4.2%
Profit Margin -3.5% -3.7% -4.4%
Rev Growth +15.5% -1.3% +12.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 99.49M 133.12M 107.62M
Total Equity 207.23M 172.35M 188.36M
D/E Ratio 0.48 0.77 0.57
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -2,559,719 -2,552,246 -2,827,370
Free Cash Flow -1,137,405 -963,691 -1,418,550